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Abstract
Drug-dependent dissociation or association of cellular receptors represents a potent pharmacologic
mode of action for regulating cell fate and function. Transferring the knowledge of pharmacologically
triggered protein-protein interactions to materials science will enable novel design concepts for
stimuli-sensing smart hydrogels. Here, we show the design and validation of an antibiotic-sensing
hydrogel for the trigger-inducible release of human vascular endothelial growth factor. Genetically
engineered bacterial gyrase subunit B (GyrB) (ref. 4) coupled to polyacrylamide was dimerized by the
addition of the aminocoumarin antibiotic coumermycin, resulting in hydrogel formation. Addition of
increasing concentrations of clinically validated novobiocin (Albamycin) dissociated the GyrB subunits,
thereby resulting in dissociation of the hydrogel and dose- and time-dependent liberation of the
entrapped protein pharmaceutical VEGF(121) for triggering proliferation of human umbilical vein
endothelial cells. Pharmacologically controlled hydrogels have the potential to fulfil the promises of
stimuli-sensing materials as smart devices for spatiotemporally controlled delivery of drugs within the
patient.
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Drug-dependent dissociation or association of cellular receptors represents a 
potent pharmacologic mode of action for regulating cell fate and function1, 2. 
Transferring the knowledge of pharmacologically-triggered protein-protein 
interactions to material science will enable novel design concepts for stimuli-
sensing smart hydrogels. Here we show the design and validation of an 
antibiotic-sensing hydrogel for the trigger-inducible release of human vascular 
endothelial growth factor3. Genetically engineered bacterial gyrase subunit B 
(GyrB4) coupled to polyacrylamide was dimerized by the addition of the 
aminocoumarin antibiotic coumermycin resulting in hydrogel formation. 
Addition of increasing concentrations of clinically validated novobiocin 
(Albamycin®) dissociated the GyrB subunits thereby resulting in dissociation of 
the hydrogel and dose- and time-dependent liberation of the entrapped protein 
pharmaceutical VEGF121 for triggering proliferation of human umbilical vein 
endothelial cells. Pharmacologically-controlled hydrogels have the potential to 
fulfill the promises of stimuli-sensing materials5-9 as smart devices for 
spatiotemporally controlled delivery of drugs within the patient. 
 
Stimuli-sensing hydrogels responsive to enzymes9-12, temperature8, light6, calcium5, 
antigens7 and DNA13 hold great promises as smart materials for drug delivery within 
the body (reviewed in 14), for tissue engineering15 or as (nano-) valves in microfluidic 
applications16. Such materials commonly respond to triggers, which are difficult to 
apply in a patient background in the case of physical stimuli (e.g. light, temperature) 
or in the case of molecule-based stimuli due to stimulus concentrations hardly 
achievable in a physiologic background (e.g. antibody concentrations in the g/l 
range7). In contrast, the mode of action for pharmaceutical substances is designed to 
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occur within physiologic limits and therefore, hydrogels based on a pharmacologic 
mode of action are expected to show high compliance with future therapeutic 
applications.  
For designing a hydrogel relying on a pharmacologic mode of action, we used the 
aminocoumarin antibiotic-dependent inhibition of bacterial gyrase, a potent target in 
combating microbial pathogens17. The antibiotic-responsive gel is based on 
polyacrylamide grafted with bacterial gyrase subunit B (GyrB), which can be 
dimerized by the aminocoumarin antibiotic coumermycin (+ Coumermycin), thereby 
resulting in gelation and three-dimensional stabilization of the hydrogel (Fig. 1a). 
Upon addition of the aminocoumarin novobiocin (Albamacin®, + Novobiocin), the 
interaction between GyrB and coumermycin is competitively inhibited, the three-
dimensional structure is loosened and the hydrogel changes to the sol-state (Fig. 1a). 
Both antibiotics bind to GyrB with a similar dissociation constant enabling an 
efficient exchange of both antibiotic species (Kd ≈ 10-8 M, the relative binding 
constants of the antibiotics to GyrB are discussed controversially18).  
As polymer we selected polyacrylamide functionalized with nitrilotriacetic acid 
(NTA) for chelating Ni2+ ions to bind hexahistidine-tagged (His6) GyrB (Fig. 1b). For 
construction of the polymer, 2,2’-(5-acrylamido-1-carboxypentylazanediyl)diacetic 
acid (NTA-AAm) was synthesized (Supplementary Fig. 1 and Supplementary Fig. 2a 
for synthesis strategy and 1H and 13C NMR data), co-polymerized with acrylamide 
(AAm, Supplementary Fig. 2a) and the NTA groups were charged with Ni2+. The 
molecular mass averages of the resulting polymer, poly(AAm-co-Ni2+-NTA-AAm), 
as determined by gel permeation chromatography, are Mw = 74.10 kDa (weight 
average molecular weight) and Mn = 11.91 kDa (number average molecular weight) 
resulting in a polydispersity index D = 6.22. The molar mass peak maximum is Mp = 
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45.4 kDa. poly(AAm-co-Ni2+-NTA-AAm) contains one NTA-AAm group per four 
acrylamide monomers as deduced from 1H NMR analysis (Supplementary Fig. 2b) 
and reflecting the stoichiometry in synthesis.  
The gene for E.coli gyrase subunit B (gyrB) was tagged with the coding sequence for 
six histidine residues. The coding region was placed under the control of the phage 
T7-derived promoter and expressed in E.coli as a soluble cytoplasmatic protein. GyrB 
was purified via the hexahistidine tag using Ni2+-based affinity chromatography 
(Supplementary Fig. 3a). Coumermycin-induced dimerization of genetically 
engineered GyrB was evaluated by incubating the protein in the presence of 
increasing coumermycin concentrations with subsequent addition of the amine-
specific bifunctional crosslinking agent dimethylsuberimidate (DMS) and analysis of 
the complexes on denaturing polyacrylamide gel electrophoresis (Supplementary Fig. 
3b). At a molar ratio of coumermycin : GyrB = 0.5, the strongest dimer formation 
(migrating at 54 kDa) could be observed in agreement with previous studies using 
non-engineered GyrB18. In order to exclude that the remaining band migrating at 27 
kDa in the presence of 0.5 moles coumermycin per mol GyrB resulted from 
inefficient antibiotic-mediated GyrB dimerization but rather from incomplete DMS-
mediated covalent crosslinking18, we performed ultrafiltration experiments. GyrB was 
incubated in the presence or absence of coumermycin and subjected to ultrafiltration 
using a 50 kDa molecular weight cut-off filter. GyrB in the absence of coumermycin 
passed the filter efficiently (54 % of protein in filtrate), whereas only background 
GyrB levels could be detected in the filtrate, when coumermycin-dimerized GyrB was 
loaded (2.8 % of protein in filtrate) indicating that coumermycin-mediated GyrB 
dimerization was quantitative.  
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Synthesis of coumermycin-crosslinked hydrogels was performed by incubating 
hexahistidine-tagged GyrB in the absence or presence of coumermycin (1 mol 
coumermycin per 2 moles GyrB) or with a ten-fold molar excess of novobiocin. The 
protein was subsequently mixed with poly(AAm-co-Ni2+-NTA-AAm) at a ratio of 
one GyrB per 11 Ni2+ ions chelated in the polymer. The solutions which all became 
viscous were incubated in PBS for 12 h prior to quantification of GyrB-polymer 
complexes released into the buffer (Fig. 2a). In the absence of coumermycin or in the 
presence of novobiocin, the viscous structures were completely dissolved and GyrB 
was quantitatively retrieved in the buffer. However, in the presence of coumermycin, 
only 13 ± 1 % of the GyrB was released into the buffer and a hydrogel was observed 
with an equilibrium degree of swelling to 146 ± 4 % of its initial volume thereby 
demonstrating the gelling effect of this dimerizing antibiotic (Fig. 2a).  
In order to demonstrate that the hydrogel formation was effectively due to GyrB 
dimerization, we synthesized hydrogels using coumermycin-dimerized GyrB as above 
or coumermycin-dimerized GyrB which had further been covalently crosslinked by 
dimethylsuberimidate (DMS, crosslinking ratio: 33 ± 4 % as judged from SDS-PAGE 
analysis, data not shown). Following swelling for 12 h in PBS, the hydrogels were 
incubated in PBS containing 1 mM novobiocin and hydrogel dissolution was 
monitored by the release of GyrB-polymer complexes into the buffer (Fig. 2b). While 
coumermycin-crosslinked hydrogels were dissolved after 11 h in the presence of 
novobiocin, hydrogels with DMS-crosslinked GyrB (+ DMS) were stable for the 
observation period of 31 h (Fig. 2b). This observation confirms that the hydrogel was 
effectively formed by coumermycin-mediated dimerization of GyrB, which could be 
reversed by excess novobiocin. Instead of dissolving, DMS-stabilized hydrogels were 
swelling in response to the addition of novobiocin (Fig. 2c), which is reflecting the 
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drug-induced elimination of coumermycin-mediated crosslinks while the covalent 
crosslinks sustained the overall gel structure (Supplementary Fig. 4).  
The gel characteristics were determined by small-strain oscillatory shear rheometry 
for hydrogels with and without covalent DMS crosslinks as described above and for 
hydrogels constructed by first mixing GyrB with poly(AAm-co-Ni2+-NTA-AAm) and 
subsequent addition of the dimerizing antibiotic coumermycin (Fig. 2d). In all 
configurations hydrogels were obtained as is evident from storage moduli G’ 
substantially exceeding loss moduli G’’ (at 1 Hz), typical of crosslinked polymer 
networks19. A storage modulus of G’ ≈ 1000 Pa was measured when GyrB was 
dimerized with coumermycin (and optionally DMS) prior to the mixing with 
poly(AAm-co-Ni2+-NTA-AAm) (Fig. 2d). When the GyrB-poly(AAm-co-Ni2+-NTA-
AAm) complex was supplemented with dimerizing coumermycin at a later time point, 
a significantly lower storage modulus (G’ = 284 ± 105, at a frequency of 1 Hz) was 
observed (Fig. 2d). This difference might reflect sterically hindered dimerization of 
GyrB already bound to poly(AAm-co-Ni2+-NTA-AAm) possibly combined with 
heterogenous distribution of coumermycin (local coumermycin : GyrB ratios different 
from 1 : 2 (mol/mol) prevent efficient GyrB dimerization, Supplementary Fig. 3b). 
Heterogenous coumermycin distribution might be favored by precipitating antibiotic 
when added at the required high concentrations to the GyrB-poly(AAm-co-Ni2+-
NTA-AAm) mix as a 50 mg/ml stock solution in DMSO. Frequency sweep rheology 
experiments between 0.1-10 Hz revealed a marked frequency-dependence of the 
viscoelastic gel properties, in contrast to polymer networks crosslinked via covalent 
bonds that are nearly frequency-independent20. Notably, at higher frequencies (>7-8 
Hz) a crossing over of G’ and G’’ was observed, indicating a reversion from a solid 
gel into a liquid state (Supplementary Figs. 5, 6, 7). The increase of the moduli at 
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higher frequencies is an indication of non-covalent “physical” crosslinks relaxing at 
higher frequencies. 
Pharmacologically-triggered hydrogel formation and dissolution opens new 
perspectives for optimal delivery of protein-based pharmaceuticals within the body, 
provided that the dissolution kinetics of the hydrogel and the release properties of the 
biopharmaceutical can optimally be adjusted into the therapeutic window. In order to 
investigate adjustable hydrogel characteristics, we incubated coumermycin-
crosslinked hydrogels in the presence of increasing novobiocin concentrations and 
followed gel dissolution by quantification of released GyrB-polymer complexes (Fig. 
3a). In the presence of 1 mM novobiocin, the hydrogel dissolved rapidly whereas 
lower novobiocin concentrations correlated with slower hydrogel dissolution and 
slower GyrB release demonstrating adjustable dissolution and release kinetics (Fig. 
3a). Apart from an initial protein release within the first few hours (Fig. 3a, probably 
due to non-efficiently incorporated GyrB), the hydrogel was stable for 24 days in the 
absence of novobiocin. Addition of 1 mM novobiocin at day 24 (+ Novo) resulted in 
dissolution of the hydrogel until day 26 demonstrating the long-term functionality of 
the hydrogel (Fig. 3b). Specificity to novobiocin was demonstrated by incubating the 
hydrogel in the presence of antibiotics of diverse classes (e.g. β-lactams (ampicillin), 
macrolides (erythromycin), aminoglycosides (gentamycin)), which did not impact on 
gel structure (data not shown). 
In order to demonstrate pharmacologically-triggered release of a therapeutic protein 
from the stimuli-sensing hydrogel, we produced the human vascular endothelial 
growth factors 121 (VEGF1213) incorporating a hexahistidine motiv at the N-terminus 
(sterical entrapment of proteins was not effective, Supplementary Fig. 8). VEGF121 
was incorporated into the hydrogel (GyrB : VEGF121 = 1000:1, mol/mol of the active 
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VEGF121 dimer) and incubated in the presence of increasing novobiocin 
concentrations (Fig. 4). In the presence of 1 mM novobiocin, VEGF121 release 
reached a plateau within 10 h, while background VEGF121 levels were observed in the 
absence of the stimulus after an initial short release of growth factor that was likely 
not well immobilized during the gelation process. At intermediate novobiocin 
concentrations (0.25 mM) VEGF121 release kinetics were slower thereby 
demonstrating the trigger-adjustable growth factor release characteristics (Fig. 4). 
Biocompatibility of the material was validated by incubating different amounts of the 
VEGF121-loaded and DMS-stabilized hydrogel (crosslinking ratio: 33±4 %) in the 
presence of the human model cell line, human embryonic kidney cells, for 48 h 
(hydrogels without additional DMS crosslinks were strongly swelling in DMEM 
medium so that they could hardly be handled any more). Although the gels contained 
sufficient VEGF121 cargo to reach a final concentration of > 500 ng/ml (more than 
five to ten-fold excess to biologically-relevant saturating concentrations21), no 
cytotoxic effects could be observed as monitored by a proliferation-based cytotoxicity 
assay (Fig. 5a). Bioactivity and bioavailability of novobiocin-released VEGF121 was 
monitored by incubating human umbilical vein endothelial cells (HUVEC21) for 96 h 
in the presence of cell culture medium containing VEGF121-loaded hydrogel further 
supplemented with 0 or 200 µM novobiocin. In the presence of novobiocin, VEGF121 
was released resulting in significantly increased proliferation of HUVEC cells while 
in the absence of the release-inducing antibiotic no difference in proliferation could 
be observed as compared to the negative control without hydrogel, indicating that the 
non-specific leakage of non- or only weakly-bound VEGF121 was not sufficient to 
produce a biologic effect. These novobiocin-triggered effects on VEGF121 release in a 
cell culture environment and subsequent activation of proliferation of human primary 
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endothelial cells demonstrate the bioactivity and bioavailability of the released growth 
factor and underline the absence of cytotoxic side effects of released gel components. 
 
In this study we have used for the first time pharmacologically controlled interactions 
between two proteins to design stimuli-responsive hydrogels for the release of a 
human growth factor in response to a clinically licensed stimulus. Novobiocin 
concentrations required for the release of a therapeutic protein out of the hydrogel can 
be maintained in the plasma over prolonged times (t½ = 6h22), a clinical phase I study 
demonstrated that novobiocin concentrations above 0.15 mM were obtained for 24-72 
h after a single oral dose23. Since novobiocin is mainly localized in the plasma, tissues 
well supplied with blood (e.g. muscle) would be the ideal localization of the hydrogel 
for trigger-inducible releasing its therapeutic cargo. Such trigger-adjustable release 
devices hold high potential in biomedical applications, since they could serve as 
economic and patient-compliant formulations for optimal administration of the 
rapidly growing number24 of protein-based biopharmaceuticals. 
 
Methods 
Production of proteins, mammalian cell culture and analytics. Cloning of 
expression vectors for GyrB and VEGF121 as well as the production, purification and 
characterization of the proteins is described in the Supplementary Information 
together with detailed information on mammalian cell culture techniques and 
analytical procedures. 
 
Synthesis of 2,2’-(5-acrylamido-1-carboxypentylazanediyl)diacetic acid (NTA-
AAm). 3.3 mmol acryloylchloride (ABCR, Karlsruhe, Germany, cat. no. AB172729) 
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dissolved in 15 ml toluene were drop wise added during 4 h to an ice-cooled solution 
of 3 mmol N,N-bis(carboxymethyl)-L-lysine (Fluka, Buchs, Switzerland, cat. no. 
14580) dissolved in 27 ml 0.44 M NaOH. The toluene was evaporated in vacuo and 
sodium ions were removed with Dowex® 50WX8 (Acros, Geel, Belgium, cat. no. 
335351000) prior to lyophilization resulting in a viscous oil (yield: 50 %) with a 
purity of  95 % as judged from 1H NMR (Supplementary Fig. 1a).  
1H-NMR (Avance 500 Bruker BioSpin AG, Fällanden, Switzerland) (D2O) δ, 1.43 
(m, 2H, CHCH2CH2CH2CH2N), 1.47 (m, 2H, CHCH2CH2CH2CH2N), 1.89 (m, 2H, 
CHCH2CH2CH2CH2N), 3.14 (t, 2H, CHCH2CH2CH2CH2N), 4.11 (m, 1H, 
CHCH2CH2CH2CH2N), 4.11 (s, 4H NCH2COOH), 5.61 (d, 1H, CHCH2), 6.03 (d, 1H, 
CHCH2), 6.11 (dd, 1H, CHCH2). 
13C-NMR (Avance 500 Bruker BioSpin AG, Fällanden, Switzerland) (D2O) δ, 23.30 
(CHCH2CH2CH2CH2N), 27.02 (CHCH2CH2CH2CH2N), 28.21 
(CHCH2CH2CH2CH2N), 39.12 (CHCH2CH2CH2CH2N), 54.68 (NCH2COOH), 67.44 
(CHCH2CH2CH2CH2N), 127.45 (CHCH2), 130.43 (CHCH2), 168.91 (NHCO), 169.95 
(CH2COOH), 171.43 (CHCOOH). 
ATR-IR (Bruker Optics IFS-66/S equipped with a liquid nitrogen-cooled MCT 
detector): 3261.1, 2941.0, 2869.6, 2522.5, 1729.9, 1650.8, 1562.1, 1417.5, 1355.7, 
1201.5, 1066.5, 975.8, 891.0, 804.2. 
MS (ES+) (LCT, Waters AG, Baden-Dättwil, Switzerland) m/z: 317.5 [M+H+]. 
 
Synthesis of poly(AAm-co-NTA-AAm). 1.5 mmol NTA-AAm and 6.4 mmol 
acrylamide (AAm, Pharmacia Biotech, Uppsala, Sweden, cat. no. 17-1300-01) were 
dissolved in 48 ml 50 mM Tris/HCl, pH 8.5 under nitrogen and polymerization was 
initiated by the addition of 150 µl ammonium peroxodisulphate (APS, 10%, w/v) and 
  11 
24 µl N,N,N’,N’-tetramethylethylenediamine (TEMED) for 20 h at room temperature. 
The polymer was concentrated to 20 ml in vacuo and subsequently dialyzed twice 
(3.5 kDa MWCO, Pierce, Rockford, IL, cat. no. 68035) against 2 l H2O for 12 h to 
eliminate salts and low molecular weight compounds like residual acrylamide. The 
obtained molar ratio of AAm to NTA-AAm was 4 to 1 as determined by 1H NMR 
(Avance 500 Bruker BioSpin AG Fällanden, Switzerland) (Supplementary Fig. 2b). 
The dialysate was supplemented with 3.5 mmol NiSO4 and dialyzed twice against 
0.5x PBS for 12 h and twice against 0.1x PBS for 12 h. The Ni2+-charged polymer 
was concentrated 10-fold in vacuo resulting in a 6 % (w/v) solution. The size of Ni2+-
charged poly(AAm-co-NTA-AAm) was analyzed by gel permeation chromatography 
on Shodex OHpak SB-806 HQ and SB-804 HQ columns (both 8.0 mm x 300 mm) 
(Showa Denko, Kawasaki, Japan) in series, using 0.1 M NaNO3 with 10% acetonitrile 
as mobile phase at a flow rate of 0.3 ml/min (Waters 2796 Alliance Bio). Detection 
was performed at 380 nm (Waters 996 PDA detector). As size standards, 
poly(styrenesulfonic acid sodium salt) (Fluka, Buchs, Switzerland) was used (Mp = 
150 kDa (cat. no. 81614), 77 kDa (81612), 32 kDa (81610), 17 kDa (81609) and 6.8 
kDa (81607)) which was detected at 260 nm. 
 
Hydrogel formation. Purified GyrB (80 mg/ml) in PBS was mixed with 
coumermycin (50 mg/ml in DMSO) at a molar ratio of GyrB : coumermycin = 2:1 
and incubated for 30 min at room temperature. Dimerized GyrB was subsequently 
added to 4.5 µl poly(AAm-co-Ni2+-NTA-AAM) (as 6 % w/v solution in PBS) per mg 
GyrB and mixed by gently stirring. The hydrogel formed immediately and was 
incubated at 4 °C in a humidified atmosphere for 20 h prior to incubating the hydrogel 
for 12 h in PBS.  
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Hydrogel characterization. For investigation of trigger-inducible hydrogel 
dissolution, the gel was incubated in PBS in the presence of different novobiocin 
(Fluka, cat. no. 74675) concentrations and the dissolution was monitored optically 
(GelJet Imager 2004, Intas, Göttingen, Germany) and by quantification of GyrB 
release into the buffer using the Bradford method. Error bars represent the standard 
deviation from three experiments. Swelling of hydrogels was quantified by 
synthesizing micro dome-shaped gels (14 µl/gel) on siliconized (Sigmacote, Sigma, 
St. Louis, MO, cat. no. SL-2) glass slides and optical analysis of the gel size using a 
Leica DM-RB microscope (Leica, Wetzlar, Germany) with built-in scale bar 
(assuming isotropic swelling). Details for the rheology measurements are shown in 
the Supplementary Information. 
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Figure legends 
 
Figure 1: Design of pharmacologically-controlled hydrogels (a) Bacterial gyrase 
subunit B (GyrB) coupled to an acrylamide polymer is dimerized by coumermycin (+ 
Coumermycin) resulting in gelation of the hydrogel. In the presence of novobiocin (+ 
Novobiocin) GyrB is dissociated resulting in dissolution of the hydrogel. (b) 
Coupling of proteins to the acrylamide polymer. Polyacrylamide is functionalized 
with nitrilotriacetic acid chelating a Ni2+ ion to which GyrB can bind via a 
hexahistidine sequence. 
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Figure 2: Synthesis and characterization of pharmacologically-controlled hydrogels. 
(a) Antibiotic-dependent hydrogel formation. His-tagged GyrB was incubated with 
coumermycin (GyrB:coumermycin = 2:1, mol/mol), novobiocin (GyrB:novobiocin = 
1:10, mol/mol) or without any antibiotic (w/o) prior to the addition of poly(AAM-co-
Ni2+-NTA-AAM). Following 12 h incubation, PBS was added and released GyrB was 
quantified after another 12 h. (b) Hydrogels were formed as described in Fig. 2a with 
coumermycin-dimerized GyrB, which was further covalently crosslinked with 
equimolar amounts of dimethylsuberimidate (+ DMS, crosslinking ratio: 33±4 %). 
Following swelling over night in PBS, the hydrogels were placed in PBS containing 1 
mM novobiocin and released GyrB was quantified. (c) Antibiotic-dependent swelling 
of DMS-stabilized hydrogels. DMS-stabilized hydrogels were prepared as described 
above (Fig. 2b) and incubated in the presence or absence of novobiocin (1 mM). 
Changes in size were monitored microscopically. (d) Viscoelastic properties of 
hydrogels. Hydrogels were prepared by first dimerizing GyrB with coumermycin and 
subsequent mixing with poly(AAm-co-Ni2+-NTA-AAm) (G-C-G + poly) or GyrB 
was first mixed with poly(AAm-co-Ni2+-NTA-AAm) prior to the addition of 
coumermycin (G-poly + C). Alternatively, DMS-crosslinked gels (G-C-GxDMS + 
poly) were used as described in Fig. 2b. The gels were swollen in PBS over night and 
the storage and the loss moduli G’ and G’’ were determined at 1.1 Hz. 
 
Figure 3: Adjustable pharmacologically triggered disintegration of the hydrogel. (a) 
Hydrogels were synthesized from (per ml hydrogel) 57.4 mg GyrB (2.1 µmol, used at 
80 mg/ml in PBS), 1.17 mg coumermycin (1.05 µmol, used at 50 mg/ml in DMSO) 
and 15.5 mg poly(AAm-co-Ni2+-NTA-AAM) (used at 6 % (w/v) in PBS). For 
synthesis, GyrB was dimerized with coumermycin for 30 min prior to mixing with 
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poly(AAm-co-Ni2+-NTA-AAM) and subsequent incubation for 20 h and a 12 h 
swelling period in PBS. Hydrogels were then incubated in new PBS in the presence of 
different novobiocin concentrations (0 - 1 mM) and hydrogel disintegration was 
measured by quantification of GyrB released into the buffer. (b) Long-term stability 
of the hydrogel. The hydrogel was incubated in PBS for 24 days prior to the addition 
of 1 mM novobiocin.  
 
Figure 4: Antibiotic-inducible release of VEGF121. Hydrogels were synthesized as 
described in Fig. 3 except that hexahistidine-tagged VEGF121 (1 mmol/mol GyrB, as 
20 µg/µl stock solution) was added to the dimerized protein prior to mixing with 
poly(AAm-co-Ni2+-NTA-AAM). The hydrogels were incubated for 24 h and 
subsequently swollen in PBS for another 48 h. The hydrogels were then incubated in 
the presence of increasing novobiocin concentrations and VEGF121 release into the 
buffer was followed over time. 
 
Figure 5: Biocompatibility of pharmacologically-triggered hydrogels and 
bioavailability of the cargo growth factor. (a) Biocompatibility of the hydrogels. 
Hydrogels with incorporated VEGF121 were prepared as described in Fig. 4 except 
that GyrB was further chemically crosslinked with equimolar amounts of 
dimethylsuberimidate for 1 h. Gels of different size were incubated for 20 h, swollen 
for another 24 h in DMEM medium containing 10 % FCS and subsequently incubated 
in the presence of human embryonic kidney cells (120’000 cells/ml) for another 48 h 
prior to quantification of cell proliferation. The grey range indicates the proliferation 
in the absence of any gel +/- 1 standard deviation (derived from 9 replicates). (b) 
Bioavailability and bioactivity of released VEGF121. Hydrogels as prepared in Fig. 5a 
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were incubated in DMEM medium containing 10 % FCS in the presence or absence 
of 200 µM novobiocin for 24 h. The supernatant containing the released VEGF121 
(and dissolved gel components) was subsequently added to HUVEC cells and 
incubated for 96 h prior to quantification of cell proliferation. As control, HUVEC 
cells were incubated in the absence of any hydrogel (w/o). 
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